The Cancer of the Pancreas Screening-5 CAPS5)Study
Launched by JOHNS HOPKINS UNIVERSITY · Nov 26, 2013
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Cancer of the Pancreas Screening (CAPS5) Study is a clinical trial aimed at finding better ways to detect pancreatic cancer early in people who may be at higher risk. This includes individuals with certain genetic conditions, like Peutz-Jeghers Syndrome or specific gene mutations, as well as those with a strong family history of pancreatic cancer. The study is currently recruiting participants aged 65 to 74 who will undergo an endoscopic evaluation of the pancreas to help doctors look for any early signs of cancer.
To be eligible for this trial, potential participants must have a hereditary condition that increases their risk of pancreatic cancer or a confirmed gene mutation linked to the disease. However, individuals with certain health issues that would make the procedure unsafe, or who cannot provide informed consent, may not be eligible. Participants can expect to undergo a procedure that involves using a thin tube with a camera to examine their pancreas closely. This study is being closely monitored to ensure safety and quality, which is an important part of any clinical trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hereditary Pancreatitis or
- • Peutz-Jeghers Syndrome or
- • Strong family history of pancreas cancer on one side of the family tree or
- • Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR
- • Endoscopic evaluation of pancreas scheduled
- Exclusion Criteria:
- • Medical comorbidities or coagulopathy that contraindicate endoscopy
- • Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
- • Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
- • Poor performance status
- • Inability to provide informed consent
- • Pregnancy.
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Pittsburgh, Pennsylvania, United States
New Haven, Connecticut, United States
Philadelphia, Pennsylvania, United States
New York, New York, United States
Baltimore, Maryland, United States
New York, New York, United States
New York, New York, United States
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Patients applied
Trial Officials
Michael Goggins, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials